The annual worldwide burden of the preventable disease cervical cancer is more than 530,000 new cases and 275,000 deaths, with the majority occurring in low- and middle-income countries (LMIC), where cervical cancer screening and early treatment are uncommon. Widely used in high-income countries, Pap smear (cytology based) screening is expensive and challenging for implementation in LMICs, where lower-cost, effective alternatives such as visual inspection with acetic acid (VIA) and rapid human papillomavirus (HPV)-based screening tests offer promise for scaling up prevention services. Integrating HPV screening with VIA in “screen-and-treat-or-refer” programs offers the dual benefits of HPV screening to maximize detection and using VIA to triage for advanced lesions/cancer, as well as a pelvic exam to address other gynecologic issues. A major issue in LMICs is coinfection with human immunodeficiency virus (HIV) and HPV, which further increases the risk for cervical cancer and marks a population with perhaps the greatest need of cervical cancer prevention. Public–private partnerships to enhance the availability of cervical cancer prevention services within HIV/AIDS care delivery platforms through initiatives such as Pink Ribbon Red Ribbon present an historic opportunity to expand cervical cancer screening in LMICs. Cancer Prev Res; 5(1); 11–17. ©2011 AACR.

Cervical cancer is a preventable malignancy, yet every year more than 530,000 women are diagnosed with and more than 275,000 women die from the disease worldwide (1). The distribution of cases and deaths is heavily weighted toward low- and middle-income countries (LMIC), which have 86% of the global cases and 88% of the total deaths (2). High-income countries have effectively integrated Pap smear–based cervical cancer screening services into both medical and public health services and have achieved reasonably high coverage rates, effectively reducing incidence and mortality over the past 7 decades (3). The expanding use of effective prophylactic vaccines for preventing infection with human papillomavirus (HPV) types 16 and 18, common etiologic agents for cervical cancer, offers even greater promise for eventual elimination of cervical cancer as a major public health problem (4, 5). Yet, continued high rates of cervical cancer in LMICs point to the failure to bring sustainable prevention programs up to a substantial scale in these countries. This gap between scientific, clinical, and public health discovery and the implementation of service delivery showcases a significant global public health failure.

George Papanicolaou invented a simple technique (cervical cytology or Pap smear) for early detection of cervical cancer by collection, smearing, and microscopic observation of desquamative cells of the cervix in 1928; the Pap smear became highly popular in higher-income nations in the 1940s (6). Cervical cytology was soon refined and adopted as a routine part of preventive care, saving lives of millions of women (7). On its face, a cytology program seems simple, yet it has multiple infrastructural and resource requirements, along with the need for awareness in the population, trained cytology technicians, and cytopathologists. With a critical lack of resources for health in general and of commitment to preventive health for women in particular, most LMICs do not have the current capacity to sustain cytology-based cervical cancer prevention programs (8). Even in venues with functioning healthcare systems, there are multiple operational factors that inhibit quality, including the follow-up challenges of multiple visits for screening and later postdiagnosis therapy, inefficient recall and referral systems, inadequate resources for screening and treatment, and competing priorities in the healthcare system. Effective cervical cancer control is uncommon in resource-limited settings (9).

The continued high incidence of cervical cancer across LMICs has prompted the development, evaluation, and adoption of innovative approaches for improving sustainable prevention efforts (Table 1). Visual inspection with acetic acid (VIA) is readily mastered by nonphysician providers and has been extensively studied as an alternative screening approach to the Pap smear (10–12). VIA gives immediate results and can be linked to cryotherapy in a relatively low-cost single-visit “see-and-treat” approach. Cryotherapy-based treatment of eligible VIA-positive lesions has been shown to be safe, feasible, acceptable, and effective in treating appropriate precancerous lesions (13, 14). Patients with cryotherapy-ineligible VIA-positive precancerous lesions and visually apparent frank invasive cervical cancer can be referred to hospitals offering excisional methods for diagnosis and treatment such as loop electrosurgical excision procedure and hysterectomy; even if advanced cancer management by surgery and chemoradiation is unavailable, many cervical cancer cases can be prevented or remediated at early stages (15, 16). More aptly called “see-and-treat-or-refer,” this cost-effective paradigm represents a pragmatic innovation for rapidly scaling up cervical cancer prevention services in LMICs.

Visualization of lesions is not the only screening alternative to Pap smears. HPV can be detected in cervical sampling by conducting a pelvic examination or through patient self-collection. HPV testing offers the most biologically compelling method of screening because virtually all cervical cancers result from chronic, persistent HPV infection (17). In comparison with other screening methods, HPV screening was superior in helping reduce both the incidence and mortality of cervical cancer in a large community-based randomized trial (18). With the ongoing development of low-cost, rapid molecular-assay technologies for HPV that are robust for field operations (19, 20), HPV-based screening has the promise to become a frontline method for cervical cancer screening, to maximize detection and expand access across LMICs. Integrating HPV testing with VIA-based “see-and-treat-or-refer” platforms can combine the high accuracy of HPV DNA testing with the same-visit benefit of triage by VIA-based screening (21–23). With innovative public–private partnerships, it can be expected that HPV screening tests would be cheap enough for widespread deployment in low-income nations.

Limited resources for disease prevention require LMIC policy makers and health care providers to evaluate the utility of individual disease control efforts through the lens of cost effectiveness (24). It is encouraging that cervical cancer prevention programs using VIA and HPV testing have “incremental cost-effectiveness ratios” (ratio of the difference between the cost of an intervention and that of the next best strategy to the change in effects due to the intervention) well below the globally accepted definitions for public health interventions judged as cost effective by public health agencies; these programs may even save money in many specific settings in which costs of the illness and its treatment exceed costs of prevention (25–27). Combining HPV vaccination with cervical cancer screening can further maximize the cost effectiveness of prevention strategies for both current and future generations of at-risk populations (27, 28).

The human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) epidemic has led to a historic health burden in LMICs, particularly in sub-Saharan Africa. The incidence, progression, and recurrence of cervical precancerous lesions are higher in HIV-infected than HIV-uninfected women. Before combination antiretroviral therapy (cART) became widely available, HIV-infected women did not live long enough for precancerous lesions to progress to cervical cancer (29). Given that cART has a limited or no impact on reducing cervical cancer rates (30), HIV-infected women who live longer on cART are at an increased risk of persistent HPV infection and cervical precancer progressing to cervical cancer. This scenario reminds HIV clinical service providers of the futility of a “surgery that is a success” even though the patient died.

Still, the natural course of cervical neoplastic disease in the context of HIV infection is not yet fully elucidated, particularly in relation to varying levels of immunosuppression and regimens of cART. And at a local level, HIV–HPV coinfection involves a complex interplay of proinflammatory cytokines and enzymatic pathways that leads to enhanced inflammatory responses in the cervicovaginal milieu (31–34). In this issue of the journal, Fitzgerald and colleagues (35) present their pilot, hypothesis-generating study suggesting that HIV is associated with increased levels of cervical cyclooxygenase 2 (COX-2) and elevated systemic prostaglandin E2 (PGE2) levels. Because PGE2 can modulate chronic inflammation–mediated carcinogenesis (36), if its elevation in HIV-positive women is confirmed in larger, prospective studies, it might serve as a useful biomarker to predict the progression of persistent HPV infection to cancer in the context of both local and systemic immunosuppression in HIV-infected women. A role for anti-inflammatory drugs, including commonly used nonsteroidal anti-inflammatory drugs, might be conceivable for prevention of inflammation-mediated cervical cancer risk, as has been shown particularly in the colorectum (37). Indeed, exogenous factors influencing cervical inflammation—for example, intrauterine devices (38), other hormonal methods for contraception (39), concurrent sexually transmitted and other infections (40), and local inflammatory changes with use of vaginal microbicides and other topical treatments (41–43)—continue to be important for understanding why only a fraction of HPV infections persist and progress to cervical cancer. Although beyond the scope of this review, recently reported observational studies have shown an increased risk of HIV acquisition linked to HPV infection (44); might HPV be a risk factor for HIV acquisition through its local immunomodulatory impact, along with its microvascular and cervical tissue physical changes (45)?

Inflammation may also be a key factor in influencing the variable response to cryotherapy-based treatment of cervical lesions in HIV-infected women (46, 47). It is possible that cryotherapy would enhance the potential for sexual transmission of HIV by HIV-infected women, given the bleeding and inflammation caused by the procedure. Similarly, HIV acquisition by at-risk uninfected women undergoing cryotherapy may be more likely because of breached integrity of the cervicovaginal mucosae. Although recently suggested to be less likely than previously assumed (48), such risk may be influenced by local PGE2-mediated inflammatory responses. Further research is needed to evaluate this risk, and if an association with PGE2 is established, local or systemic treatment by anti-inflammatory agents may augment advice about temporary abstinence and use of condoms in preventing sexual transmission or acquisition of HIV after cryotherapy.

The study by Fitzgerald and colleagues (35) is hypothesis generating and highlights an important consideration for implementing screening strategies, particularly for HIV-infected women. Cervical cancer screening strategies that use HPV-based screening via self-collection as the first-line approach can reduce the burden of pelvic examinations for women who test HPV negative because the high negative predictive value of HPV DNA testing provides reassurance of safety against current risk for cervical cancer (49). However, an undesirable side effect of this approach is that HPV-negative women end up not receiving a detailed pelvic examination in the context of cervical cancer screening. Because resource limitations often preclude follow-up visits, this “once-in-a-lifetime” self-collection–based approach for HPV-based screening, although saving costs and resources for HPV testing, may in fact represent a missed opportunity for evaluating risk for other cervical conditions in HPV-negative women, including evaluation of cervical inflammation. Therefore, we believe that it is important to emphasize the need for at least one pelvic examination when offering cervical cancer screening services for HIV-infected women, ideally accompanied by evaluation for other gynecologic conditions (including local inflammation and infection-associated changes) and appropriate treatment for sexually transmitted infections. Only a small minority of women has been screened even once in a lifetime in lower-income nations; it is therefore vital to emphasize the importance of a pelvic examination as part of routine reproductive healthcare services for all women and, especially, for those with immunosuppressive illnesses.

Cervical cancer prevention with a woman-centric approach is amenable to effective integration with other public health programs being implemented in LMICs (15, 50, 51). Since the advent of the President's Emergency Plan for AIDS Relief (PEPFAR) in 2003, the global community has experienced a major surge in funding for prevention and treatment of HIV/AIDS and other infectious diseases in LMICs. The clinical infrastructures being created or expanded through PEPFAR, the Global Fund to Fight AIDS, Tuberculosis and Malaria, and the World Bank offer historic opportunities to integrate cervical cancer screening services with expanded HIV screening and care infrastructures. As described by the U.S. State Department, the September 2011 launch of the Pink Ribbon Red Ribbon campaign is expanding “the availability of vital cervical cancer screening and treatment—especially for high-risk HIV-positive women—and also promot[ing] breast cancer education” (http://www.state.gov/r/pa/prs/ps/2011/09/172244.htm). This initiative was inspired by the success of PEPFAR-supported implementation initiatives such as our Cervical Cancer Prevention Program in Zambia (CCPPZ; refs. 15, 52). Now a routine part of public sector services, we are effectively delivering cervical cancer prevention services to HIV-infected and other at-risk women with nurses (Fig. 1) as frontline care providers (16, 53). CCPPZ has also pioneered the use of digital cervicographic adjunct to routine VIA screening, thereby achieving efficiencies in quality assurance and provider retraining, as well as providing an opportunity for bedside patient education and feedback (53). Furthermore, digital cervicography has allowed internet and cell-phone–based clinical consultations at a distance between nurses in peripheral clinics and gynecologists located centrally, thereby allowing efficient utilization of health care manpower through a “hub and spoke” model (54). Thousands of precancerous lesions and hundreds of cancers have been treated (and deaths prevented) in this program that has now screened more than 65,000 women over 5 years (15).

Can HPV vaccine be helpful in HIV-infected women? Little is known about the utility of HPV vaccine in HIV-infected women, but arguments are compelling that women who are not infected with HPV types 16 or 18 may benefit from vaccination even if they are not in the lower-age target group of virginal girls (55). Many women globally are infected with oncogenic strains of HPV but not yet with types 16 or 18, suggesting that vaccine protection from the HPV types would be helpful (56–58). Of course, multivalent vaccines now in development should protect against even more oncogenic HPV types of relevance to women in LMICs. Combination prevention efforts are being advocated for HIV control in LMICs (59–64). Can we afford to do less for HPV control, where combining vaccination with screening/treatment could maximize long-term and immediate impact (65)? For example, platforms for screening can be extended to also vaccinate at-risk populations; or existing vaccination programs can be extended to also screen at-risk women. A “mother-daughter” program of HPV screening (for mothers) and HPV vaccination (for daughters), for example, may maximize impact by dovetailing with ongoing programs and existing infrastructures.

We are confident that affordable screening for cervical cancer is feasible and effective in LMICs (5, 11, 15, 16, 52, 53). Along with the Pink Ribbon Red Ribbon campaign organizers, we believe it is an opportune time for expanding cancer prevention initiatives nested within ongoing public health programs in LMICs. Vertical programs, such as HIV screening, also should be broadened to include cancer screening. Although immunosuppressed women are of special concern, mitigation of risk through pragmatic clinical prevention services, including HPV vaccine, can be expanded to reach a wide swath of at-risk women in an implementation catchment area. A concerted push by key stakeholders—clinicians, public health professionals, researchers, politicians, policy makers, and women themselves—is needed to build on this momentum and dramatically enhance cost-effective cervical cancer screening and treatment to prevent unnecessary deaths of women in LMICs.

No potential conflicts of interest were disclosed.

1.
Ferlay
J
,
Shin
HR
,
Bray
F
,
Forman
D
,
Mathers
C
,
Parkin
DM
. 
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
.
Int J Cancer
2010
;
127
:
2893
917
.
2.
Jemal
A
,
Bray
F
,
Center
MM
,
Ferlay
J
,
Ward
E
,
Forman
D
. 
Global cancer statistics
.
CA Cancer J Clin
2011
;
61
:
69
90
.
3.
Forouzanfar
MH
,
Foreman
KJ
,
Delossantos
AM
,
Lozano
R
,
Lopez
AD
,
Murray
CJ
, et al
Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis
.
Lancet
2011
;
378
:
1461
84
.
4.
Kane
MA
. 
Preventing cancer with vaccines: Progress in the global control of cancer
.
Cancer Prev Res
2012
;
5
:
24
9
.
5.
Lowy
DR
,
Schiller
JT
. 
Reducing HPV-associated cancer globally
.
Cancer Prev Res
2012
;
5
:
18
23
.
6.
Papanicolaou
GN
,
Traut
HF
. 
The diagnostic value of vaginal smears in carcinoma of the uterus
.
1941
.
Arch Pathol Lab Med
1997
;
121
:
211
24
.
7.
Kitchener
HC
,
Castle
PE
,
Cox
JT
. 
Chapter 7: Achievements and limitations of cervical cytology screening
.
Vaccine
2006
;
24
Suppl 3:S3/63–70
.
8.
Sankaranarayanan
R
,
Budukh
AM
,
Rajkumar
R
. 
Effective screening programmes for cervical cancer in low- and middle-income developing countries
.
Bull World Health Organ
2001
;
79
:
954
62
.
9.
Gakidou
E
,
Nordhagen
S
,
Obermeyer
Z
. 
Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities
.
PLoS Med
2008
;
5
:
e132
.
10.
Sauvaget
C
,
Fayette
JM
,
Muwonge
R
,
Wesley
R
,
Sankaranarayanan
R
. 
Accuracy of visual inspection with acetic acid for cervical cancer screening
.
Int J Gynaecol Obstet
2011
;
113
:
14
24
.
11.
Sahasrabuddhe
VV
,
Bhosale
RA
,
Kavatkar
AN
,
Nagwanshi
CA
,
Joshi
SN
,
Jenkins
CA
, et al
Comparison of visual inspection with acetic acid and cervical cytology to detect high-grade cervical neoplasia among HIV-infected women in India
.
Int J Cancer
2012
;
130
:
234
40
.
12.
Sankaranarayanan
R
,
Nessa
A
,
Esmy
PO
,
Dangou
JM
. 
Visual inspection methods for cervical cancer prevention
.
Best Pract Res Clin Obstet Gynaecol
2011 Nov 8
.
[Epub ahead of print]
.
13.
Sankaranarayanan
R
,
Esmy
PO
,
Rajkumar
R
,
Muwonge
R
,
Swaminathan
R
,
Shanthakumari
S
, et al
Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial
.
Lancet
2007
;
370
:
398
406
.
14.
Sankaranarayanan
R
,
Rajkumar
R
,
Esmy
PO
,
Fayette
JM
,
Shanthakumary
S
,
Frappart
L
, et al
Effectiveness, safety and acceptability of ‘see and treat’ with cryotherapy by nurses in a cervical screening study in India
.
Br J Cancer
2007
;
96
:
738
43
.
15.
Mwanahamuntu
MH
,
Sahasrabuddhe
VV
,
Kapambwe
S
,
Pfaendler
KS
,
Chibwesha
C
,
Mkumba
G
, et al
Advancing cervical cancer prevention initiatives in resource-constrained settings: insights from the Cervical Cancer Prevention Program in Zambia
.
PLoS Med
2011
;
8
:
e1001032
.
16.
Pfaendler
KS
,
Mwanahamuntu
MH
,
Sahasrabuddhe
VV
,
Mudenda
V
,
Stringer
JS
,
Parham
GP
. 
Management of cryotherapy-ineligible women in a “screen-and-treat” cervical cancer prevention program targeting HIV-infected women in Zambia: lessons from the field
.
Gynecol Oncol
2008
;
110
:
402
7
.
17.
Schiffman
M
,
Wentzensen
N
,
Wacholder
S
,
Kinney
W
,
Gage
JC
,
Castle
PE
. 
Human papillomavirus testing in the prevention of cervical cancer
.
J Natl Cancer Inst
2011
;
103
:
368
83
.
18.
Sankaranarayanan
R
,
Nene
BM
,
Shastri
SS
,
Jayant
K
,
Muwonge
R
,
Budukh
AM
, et al
HPV screening for cervical cancer in rural India
.
N Engl J Med
2009
;
360
:
1385
94
.
19.
Qiao
YL
,
Sellors
JW
,
Eder
PS
,
Bao
YP
,
Lim
JM
,
Zhao
FH
, et al
A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China
.
Lancet Oncol
2008
;
9
:
929
36
.
20.
Yang
HP
,
Walmer
DK
,
Merisier
D
,
Gage
JC
,
Bell
L
,
Rangwala
S
, et al
A pilot analytic study of a research-level, lower-cost human papillomavirus 16, 18, and 45 test
.
J Virol Methods
2011
;
176
:
112
4
.
21.
Wiwanitkit
V
. 
Screening for cervical cancer: which common technique is the most cost-effective choice?
Asian Pac J Cancer Prev
2009
;
10
:
531
2
.
22.
Shastri
SS
,
Dinshaw
K
,
Amin
G
,
Goswami
S
,
Patil
S
,
Chinoy
R
, et al
Concurrent evaluation of visual, cytological and HPV testing as screening methods for the early detection of cervical neoplasia in Mumbai, India
.
Bull World Health Organ
2005
;
83
:
186
94
.
23.
Cuzick
J
,
Arbyn
M
,
Sankaranarayanan
R
,
Tsu
V
,
Ronco
G
,
Mayrand
MH
, et al
Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries
.
Vaccine
2008
;
26
Suppl 10
:
K29
41
.
24.
Goldhaber-Fiebert
JD
,
Denny
LA
,
De Souza
M
,
Kuhn
L
,
Goldie
SJ
. 
Program spending to increase adherence: South African cervical cancer screening
.
PLoS One
2009
;
4
:
e5691
.
25.
Goldie
SJ
,
Gaffikin
L
,
Goldhaber-Fiebert
JD
,
Gordillo-Tobar
A
,
Levin
C
,
Mahé
C
, et al
Cost-effectiveness of cervical-cancer screening in five developing countries
.
N Engl J Med
2005
;
353
:
2158
68
.
26.
Vanni
T
,
Luz
PM
,
Grinsztejn
B
,
Veloso
VG
,
Foss
A
,
Mesa-Frias
M
, et al
Cervical cancer screening among HIV-infected women: An economic evaluation in a middle-income country
.
Int J Cancer
2011 Sep 30
[Epub ahead of print]
.
27.
Diaz
M
,
Kim
JJ
,
Albero
G
,
de Sanjosé
S
,
Clifford
G
,
Bosch
FX
, et al
Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India
.
Br J Cancer
2008
;
99
:
230
8
.
28.
Campos
NG
,
Kim
JJ
,
Castle
PE
,
Ortendahl
JD
,
O'Shea
M
,
Diaz
M
, et al
Health and economic impact of HPV 16/18 vaccination and cervical cancer screening in Eastern Africa
.
Int J Cancer
2011 Jun 29
[Epub ahead of print]
.
29.
Franceschi
S
,
Jaffe
H
. 
Cervical cancer screening of women living with HIV infection: a must in the era of antiretroviral therapy
.
Clin Infect Dis
2007
;
45
:
510
3
.
30.
Bratcher
LF
,
Sahasrabuddhe
VV
. 
The impact of antiretroviral therapy on HPV and cervical intraepithelial neoplasia: current evidence and directions for future research
.
Infect Agent Cancer
2010
;
5
:
8
.
31.
Behbahani
H
,
Walther-Jallow
L
,
Klareskog
E
,
Baum
L
,
French
AL
,
Patterson
BK
, et al
Proinflammatory and type 1 cytokine expression in cervical mucosa during HIV-1 and human papillomavirus infection
.
J Acquir Immune Defic Syndr
2007
;
45
:
9
19
.
32.
Mkhize
NN
,
Gumbi
PP
,
Liebenberg
LJ
,
Ren
Y
,
Smith
P
,
Denny
L
, et al
Persistence of genital tract T cell responses in HIV-infected women on highly active antiretroviral therapy
.
J Virol
2010
;
84
:
10765
72
.
33.
Henning
TR
,
Kissinger
P
,
Lacour
N
,
Meyaski-Schluter
M
,
Clark
R
,
Amedee
AM
. 
Elevated cervical white blood cell infiltrate is associated with genital HIV detection in a longitudinal cohort of antiretroviral therapy-adherent women
.
J Infect Dis
2010
;
202
:
1543
52
.
34.
Hirbod
T
,
Nilsson
J
,
Andersson
S
,
Uberti-Foppa
C
,
Ferrari
D
,
Manghi
M
, et al
Upregulation of interferon-alpha and RANTES in the cervix of HIV-1-seronegative women with high-risk behavior
.
J Acquir Immune Defic Syndr
2006
;
43
:
137
43
.
35.
Fitzgerald
DW
,
Bezak
K
,
Ocheretina
O
, et al
The effect of HIV and HPV co-infection on cervical COX-2 expression and systemic prostaglandin E2 Levels
.
Cancer Prev Res
2012
;
5
:
34
40
.
36.
Greenhough
A
,
Smartt
HJ
,
Moore
AE
,
Roberts
HR
,
Williams
AC
,
Paraskeva
C
, et al
The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment
.
Carcinogenesis
2009
;
30
:
377
86
.
37.
Chan
AT
. 
Aspirin and familial adenomatous polyposis: coming full circle
.
Cancer Prev Res
2011
;
4
:
623
7
.
38.
Castellsagué
X
,
Díaz
M
,
Vaccarella
S
,
de Sanjosé
S
,
Muñoz
N
,
Herrero
R
, et al
Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: a pooled analysis of 26 epidemiological studies
.
Lancet Oncol
2011
;
12
:
1023
31
.
39.
Marks
M
,
Gravitt
PE
,
Gupta
SB
,
Liaw
KL
,
Tadesse
A
,
Kim
E
, et al
Combined oral contraceptive use increases HPV persistence but not new HPV detection in a cohort of women from Thailand
.
J Infect Dis
2011
;
204
:
1505
13
.
40.
Al-Daraji
WI
,
Smith
JH
. 
Infection and cervical neoplasia: facts and fiction
.
Int J Clin Exp Pathol
2009
;
2
:
48
64
.
41.
Zehbe
I
,
Richard
C
,
Lee
KF
,
Campbell
M
,
Hampson
L
,
Hampson
IN
. 
Lopinavir shows greater specificity than zinc finger ejecting compounds as a potential treatment for human papillomavirus-related lesions
.
Antiviral Res
2011
;
91
:
161
6
.
42.
Roberts
JN
,
Kines
RC
,
Katki
HA
,
Lowy
DR
,
Schiller
JT
. 
Effect of Pap smear collection and carrageenan on cervicovaginal human papillomavirus-16 infection in a rhesus macaque model
.
J Natl Cancer Inst
2011
;
103
:
737
43
.
43.
Van Pachterbeke
C
,
Bucella
D
,
Rozenberg
S
,
Manigart
Y
,
Gilles
C
,
Larsimont
D
, et al
Topical treatment of CIN 2 +by cidofovir: results of a phase II, double-blind, prospective, placebo-controlled study
.
Gynecol Oncol
2009
;
115
:
69
74
.
44.
Auvert
B
,
Marais
D
,
Lissouba
P
,
Zarca
K
,
Ramjee
G
,
Williamson
AL
. 
High-risk human papillomavirus is associated with HIV acquisition among South African female sex workers
.
Infect Dis Obstet Gynecol
2011
;
2011:692012
.
45.
van der Loeff
MF
,
Nyitray
AG
,
Giuliano
AR
. 
HPV vaccination to prevent HIV infection: time for randomized controlled trials
.
Sex Transm Dis
2011
;
38
:
640
3
.
46.
Taylor
S
,
Wang
C
,
Wright
TC
,
Denny
L
,
Tsai
WY
,
Kuhn
L
. 
Reduced acquisition and reactivation of human papillomavirus infections among older women treated with cryotherapy: results from a randomized trial in South Africa
.
BMC Med
2010
;
8
:
40
.
47.
Tate
DR
,
Anderson
RJ
. 
Recrudescence of cervical dysplasia among women who are infected with the human immunodeficiency virus: a case-control analysis
.
Am J Obstet Gynecol
2002
;
186
:
880
2
.
48.
Chung
MH
,
McKenzie
KP
,
Richardson
BA
,
John-Stewart
GC
,
Coombs
RW
,
De Vuyst
H
, et al
Cervical HIV-1 RNA shedding after cryotherapy among HIV-positive women with cervical intraepithelial neoplasia stage 2 or 3
.
AIDS
2011
;
25
:
1915
9
.
49.
Gage
JC
,
Castle
PE
. 
Preventing cervical cancer globally by acting locally: if not now, when?
J Natl Cancer Inst
2010
;
102
:
1524
7
.
50.
Teguete
I
,
Muwonge
R
,
Traore
C
,
Dolo
A
,
Bayo
S
,
Sankaranarayanan
R
. 
Can visual cervical screening be sustained in routine health services? Experience from Mali, Africa
.
BJOG
2011 Sep 6
[Epub ahead of print]
.
51.
Mutyaba
T
,
Mirembe
F
,
Sandin
S
,
Weiderpass
E
. 
Evaluation of ‘see-see and treat’ strategy and role of HIV on cervical cancer prevention in Uganda
.
Reprod Health
2010
;
7
:
4
.
52.
Parham
GP
,
Mwanahamuntu
MH
,
Sahasrabuddhe
VV
,
Westfall
AO
,
King
KE
,
Chibwesha
C
.et al 
Implementation of cervical cancer prevention services for HIV-infected women in Zambia: measuring program effectiveness
.
HIV Ther
2010
;
4
:
713
22
.
53.
Mwanahamuntu
MH
,
Sahasrabuddhe
VV
,
Pfaendler
KS
,
Mudenda
V
,
Hicks
ML
,
Vermund
SH
, et al
Implementation of ‘see-and-treat’ cervical cancer prevention services linked to HIV care in Zambia
.
AIDS
2009
;
23
:
N1
5
.
54.
Parham
GP
,
Mwanahamuntu
MH
,
Pfaendler
KS
,
Sahasrabuddhe
VV
,
Myung
D
,
Mkumba
G
, et al
eC3–a modern telecommunications matrix for cervical cancer prevention in Zambia
.
J Low Genit Tract Dis
2010
;
14
:
167
73
.
55.
Castellsague
X
,
Schneider
A
,
Kaufmann
AM
,
Bosch
FX
. 
HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives
.
Gynecol Oncol
2009
;
115
:
S15
23
.
56.
Castellsagué
X
,
Díaz
M
,
de Sanjosé
S
,
Muñoz
N
,
Herrero
R
,
Franceschi
S
, et al
Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention
.
J Natl Cancer Inst
2006
;
98
:
303
15
.
57.
Sahasrabuddhe
VV
,
Mwanahamuntu
MH
,
Vermund
SH
,
Huh
WK
,
Lyon
MD
,
Stringer
JS
, et al
Prevalence and distribution of HPV genotypes among HIV-infected women in Zambia
.
Br J Cancer
2007
;
96
:
1480
3
.
58.
Bollen
LJ
,
Chuachoowong
R
,
Kilmarx
PH
,
Mock
PA
,
Culnane
M
,
Skunodom
N
, et al
Human papillomavirus (HPV) detection among human immunodeficiency virus-infected pregnant Thai women: implications for future HPV immunization
.
Sex Transm Dis
2006
;
33
:
259
64
.
59.
Rotheram-Borus
MJ
,
Swendeman
D
,
Chovnick
G
. 
The past, present, and future of HIV prevention: integrating behavioral, biomedical, and structural intervention strategies for the next generation of HIV prevention
.
Annu Rev Clin Psychol
2009
;
5
:
143
67
.
60.
Buchbinder
S
. 
HIV epidemiology, testing strategies, and prevention interventions
.
Top HIV Med
2010
;
18
:
38
44
.
61.
Kurth
AE
,
Celum
C
,
Baeten
JM
,
Vermund
SH
,
Wasserheit
JN
. 
Combination HIV prevention: significance, challenges, and opportunities
.
Curr HIV/AIDS Rep
2011
;
8
:
62
72
.
62.
Matovu
JK
. 
Preventing HIV transmission in married and cohabiting HIV-discordant couples in sub-Saharan Africa through combination prevention
.
Curr HIV Res
2010
;
8
:
430
40
.
63.
Burns
DN
,
Dieffenbach
CW
,
Vermund
SH
. 
Rethinking prevention of HIV type 1 infection
.
Clin Infect Dis
2010
;
51
:
725
31
.
64.
Vermund
SH
,
Allen
KL
,
Karim
QA
. 
HIV-prevention science at a crossroads: advances in reducing sexual risk
.
Curr Opin HIV AIDS
2009
;
4
:
266
73
.
65.
Stanley
M
. 
Human papillomavirus vaccines versus cervical cancer screening
.
Clin Oncol
(
R Coll Radiol
) 
2008
;
20
:
388
94
.